Neurocrine Biosciences reported $30.5M in Pre-Tax Profit for its third fiscal quarter of 2021.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Pre Tax Profit Change
Acadia Pharmaceuticals ACAD:US $ -14.79M 28.61M
Adamas Pharmaceuticals ADMS:US -19518000 7.17M
Agios Pharmaceuticals AGIO:US $ -84.26M 1.47M
Alexion Pharmaceuticals ALXN:US $ 940.1M 164.6M
Alnylam Pharmaceuticals ALNY:US $ -212.93M 24.6M
Biogen BIIB:US $ 814.2M 255M
Cytokinetics CYTK:US $ -76.09M 14.53M
Enanta Pharmaceuticals ENTA:US $ -33.39M 0.01M
Exelixis EXEL:US $ 53.26M 71.63M
Halozyme Therapeutics HALO:US $ 74.11M 17.41M
Intercept Pharmaceuticals ICPT:US $ -3.63M 7.46M
Intra Cellular Therapies ITCI:US $ -76.93M 8.21M
IONIS PHARMACEUT IONS:US $ -84M 3M
Nektar Therapeutics NKTR:US $ -129.59M 4.43M
Neurocrine Biosciences NBIX:US $ 30.5M 27M
Prothena PRTA:US $ 109.2M 81.3M
Regeneron Pharmaceuticals REGN:US $ 1822.2M 2076.1M
Repligen RGEN:US $ 55.91M 0.3M
Rigel Pharmaceuticals RIGL:US $ -21.09M 6.3M
Sarepta Therapeutics SRPT:US $ -47.91M 33.85M
Teva Pharmaceutical TEVA:IT 382M 412M
Ultragenyx Pharmaceutical RARE:US $ -72.82M 49.15M
Xoma XOMA:US $ -4.44M 2.2M
Zogenix ZGNX:US $ -58M 0.89M